301 related articles for article (PubMed ID: 9932086)
21. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
22. Schedule-dependent efficacy of camptothecins in models of human cancer.
Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
[No Abstract] [Full Text] [Related]
23. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
25. Camptothecins: new enthusiasm for an old drug.
Rowe PM
Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
[No Abstract] [Full Text] [Related]
26. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.
Kohn KW; Pommier Y
Ann N Y Acad Sci; 2000; 922():11-26. PubMed ID: 11193886
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical trials of topoisomerase inhibitors.
Saijo N
Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
[TBL] [Abstract][Full Text] [Related]
29. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
30. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Mitsui I; Kumazawa E; Hirota Y; Aonuma M; Sugimori M; Ohsuki S; Uoto K; Ejima A; Terasawa H; Sato K
Jpn J Cancer Res; 1995 Aug; 86(8):776-82. PubMed ID: 7559102
[TBL] [Abstract][Full Text] [Related]
31. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Jun; 4(3):152-67. PubMed ID: 11768329
[TBL] [Abstract][Full Text] [Related]
32. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
Bailly C
Crit Rev Oncol Hematol; 2003 Jan; 45(1):91-108. PubMed ID: 12482574
[TBL] [Abstract][Full Text] [Related]
33. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
[TBL] [Abstract][Full Text] [Related]
34. Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin.
Li M; Tang W; Zeng F; Lou L; You T
Bioorg Med Chem Lett; 2008 Dec; 18(24):6441-3. PubMed ID: 18986807
[TBL] [Abstract][Full Text] [Related]
35. Promising new agents in oncologic treatment.
Mani S; Ratain MJ
Curr Opin Oncol; 1996 Nov; 8(6):525-34. PubMed ID: 8971473
[TBL] [Abstract][Full Text] [Related]
36. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
37. Current perspectives on camptothecins in cancer treatment.
Dancey J; Eisenhauer EA
Br J Cancer; 1996 Aug; 74(3):327-38. PubMed ID: 8695345
[TBL] [Abstract][Full Text] [Related]
38. Treatment of central nervous system xenografts with camptothecins.
Friedman HS; Houghton PJ
Ann N Y Acad Sci; 1996 Dec; 803():210-2. PubMed ID: 8993514
[No Abstract] [Full Text] [Related]
39. The camptothecins.
Pizzolato JF; Saltz LB
Lancet; 2003 Jun; 361(9376):2235-42. PubMed ID: 12842380
[TBL] [Abstract][Full Text] [Related]
40. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]